natgillin/translations-raw huggingface dataset:
Follow-up analysis of INCIVO-treated patients who did not achieve an SVR showed that the population of wild-type virus increased and the population of telaprevir-resistant variants became undetectable over time after the end of telaprevir treatment. 
Analiza praćenih bolesnika liječenih INCIVOM koji nisu postigli SVR pokazala je da je populacija divljeg tipa virusa s vremenom rasla, a populacija varijanti rezistentnih na telaprevir postala nemjerljiva nakon završetka liječenja telaprevirom.
The direction of the arrow (↑ = increase, ↓ = decrease, ↔ = no change) for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (↔), below (↓) or above (↑) the 80-125% range. 
Smjer strjelice (↑ = povećanje, ↓ = smanjenje, ↔ = bez promjene) za svaki farmakokinetički parametar temelji se na intervalu pouzdanosti od 90% geometrijske sredine omjera koji je unutar (↔), ispod (↓) ili iznad (↑) raspona od 80% do 125%.
Caution is warranted and clinical monitoring is recommended when intravenous lidocaine is administered for the treatment of acute ventricular arrhythmia. 
Nalaže se oprez i preporučuje klinički nadzor kad se intravenski lidokain primjenjuje za liječenje akutne ventrikularne aritmije.
To prevent treatment failure, the dose of INCIVO must not be reduced or interrupted. 
Kako bi se spriječio neuspjeh liječenja, ne smije se smanjiti doza niti prekinuti primjena INCIVA.
For additional information on mild to moderate rash, see section 4.8. 
Za dodatne informacije o blagom do umjerenom osipu, vidjeti dio 4.8.
HCV RNA levels should be monitored at weeks 4 and 12 and as clinically indicated (see also guidelines for discontinuation of INCIVO, section 4.2). 
Vrijednosti HCV RNK treba pratiti u 4. i 12. tjednu te kad je to klinički indicirano (vidjeti također smjernice za prestanak primjene INCIVA, dio 4.2).
IL28B genotype CC 
IL28B genotip
If you are breast-feeding, you must stop breast-feeding before starting to take INCIVO. 
Ako dojite, morate prestati dojiti prije početka uzimanja INCIVA.
Note that the virologic stopping rules taken into account in this treatment outcome analysis are actual stopping rules, i.e., those derived from disposition and exposure data, as opposed to mathematical stopping rules, i.e., derived from the 
Napomena, virološka pravila za prekid uzeta u obzir u ovoj analizi ishoda liječenja, su stvarna pravila za prekid, tj. ona izvedena iz podataka dispozicije i izloženosti, što je suprotno od matematičkih pravila za prekid, npr. izvedenih iz HCV RNK podataka.
Efficacy in adults with HCV/HIV-1 co-infection 
Djelotvornost u odraslih s istodobnom HCV/HIV-1 infekcijom
Yellow caplet-shaped tablets of approximately 20 mm in length, marked with ‘T375' on one side. 
Žute tablete ovalnog oblika duljine oko 20 mm, s oznakom “T375” na jednoj strani.
Contact your doctor immediately also if you develop any of the following symptoms: - tiredness, weakness, shortness of breath, light-headedness, and/or feeling of heart racing. 
Odmah se javite liječniku i ako se razvije neki od sljedećih simptoma: - umor, slabost, nedostatak daha, ošamućenost i/ili osjećate ubrzan rad srca.
Median (range) CD4 cell count at baseline was 651 (277 to 1,551 cells/mm 
Medijan (raspon) broja CD4 stanica na početku bio je 651 (277 do 1551 stanica/mm
- if you have a wide-spread rash with peeling skin which may be accompanied by fever, flu-like symptoms, painful skin blisters, and blisters in the mouth, eyes, and/or genitals. 
- ako imate prošireni osip s ljuštenjem kože koji može biti praćen vrućicom, simptomima sličnima gripi, bolnim mjehurićima na koži i mjehurićima u ustima, na očima i/ili spolnim
Concomitant administration with Class Ia or III antiarrhythmics, except for intravenous lidocaine (see section 4.5). 
Istodobna primjena s antiaritmicima skupine Ia ili III, osim intravenskog lidokaina (vidjeti dio 4.5).
Refer to sections 4.4 and 4.6. 
Vidjeti dijelove 4.4 i 4.6.
If ribavirin is permanently discontinued for the management of anaemia, INCIVO must also be permanently discontinued. 
Ako se primjena ribavirina trajno prekine radi zbrinjavanja anemije, mora se trajno prekinuti i primjena INCIVA.
Carbamazepine, phenytoin and phenobarbital 
Karbamazepin, fenitoin i fenobarbital
Use of INCIVO should be avoided in patients with congenital QT prolongation, or a family history of congenital QT prolongation or sudden death. 
Primjenu INCIVA treba izbjegavati u bolesnika s kongenitalnim produljenjem QT intervala ili s kongenitalnim produljenjem QT intervala ili iznenadnom smrću u obiteljskoj anamnezi.
Tablet film-coat polyvinyl alcohol macrogol talc titanium dioxide (E171) iron oxide yellow (E172) 
Film ovojnica tablete polivinilni alkohol, makrogol, talk, titanijev dioksid (E171), željezov oksid, žuti (E172)
Prescribers should ensure that patients are fully informed about the risk of severe rashes, and to consult with their prescriber immediately if they develop a new rash or worsening of an existing rash. 
Liječnici koji propisuju lijek trebaju bolesnike u potpunosti upoznati s rizikom pojave teških osipa te ih upozoriti da se odmah moraju javiti liječniku ako se pojavi novi ili pogorša postojeći osip.
Please consult sections 4.4 and 5.1 regarding the selection of peginterferon alfa-2a or -2b. 
Molimo vidjeti dijelove 4.4 i 5.1 vezano uz odabir peginterferona alfa-2a ili -2b.
After oral administration, the typical apparent volume of distribution (Vd) was estimated to be 252 l, with an inter-individual variability of 72.2%. 
Nakon peroralne primjene, tipični prividni volumen raspodjele (Vd) približno je bio 252 l, uz varijacije između osoba od 72,2%.
The pharmacokinetics of telaprevir were assessed after administration of a single dose of 750 mg to HCV-negative subjects with severe renal impairment (CrCl < 30 ml/min). 
Farmakokinetika telaprevira procijenila se nakon primjene jednokratne doze od 750 mg u HCV negativnih ispitanika s teškim oštećenjem funkcije bubrega (CrCl < 30 ml/min).
In clinical trials, the majority of these events (e.g., haemorrhoids, anorectal discomfort, anal pruritus, and rectal burning) were mild to moderate, very few led to treatment discontinuation and resolved after completion of INCIVO dosing. 
U kliničkim je ispitivanjima većina ovih događaja (npr. hemoroidi, anorektalna nelagoda, analni svrbež i rektalno žarenje) bila blaga do umjerena, dok su u vrlo malog broja bolesnika doveli do prestanka liječenja i povukli se nakon završetka primjene INCIVA.
Telaprevir readily crosses the placenta in both rat and mouse giving a foetal: maternal exposure of 19 - 50%. 
Telaprevir lako prolazi posteljicu u štakora i miša, čime omjer izloženosti fetusa i majke iznosi od 19% do 50%.
Telaprevir is a weak in vitro inhibitor of the transporters multidrug and toxin extrusion (MATE) MATE1 and MATE2-K with an IC50 of 28.3 μM and 32.5 μM, respectively. 
In vitro, telaprevir je slab inhibitor transportera više lijekova i toksina ekstruzije (MATE) MATE1 i MATE2-K uz IC50 od 28,3 μM odnosno 32,5 μM.
In a fertility and early embryonic development study in rats, an increase in non-viable conceptuses was observed. 
U ispitivanjima utjecaja na plodnost i rani embrionalni razvoj u štakora primijećeno je povećanje neživih zametaka.
Toxic epidermal necrolysis (TEN) including fatal outcome has been observed in post-marketing experience (see section 4.8). 
Toksična epidermalna nekroliza (TEN), uključujući onu s fatalnim ishodom, zabilježena je nakon stavljanja lijeka u promet (vidjeti dio 4.8).
clarithromycin, erythromycin, telithromycin, troleandomycin to treat bacterial infections (antibacterials) 
klaritromicin, eritromicin, telitromicin, troleandomicin za liječenje bakterijskih infekcija (antibiotici)
No relevant inhibition by telaprevir of the organic cation transporter (OCT) OCT2 was observed in vitro. 
In vitro nije zabilježena relevantna inhibicija organskih kation transportera (OCT) OCT2 telaprevirom.
Of the 393 resistant variants detected in the 255 patients, 68% of NS3-36, 84% of NS3-54, 59% of NS3-155, 86% of NS3-156, and 52% of NS3-36M+NS3-155K variants were no longer detected. 
Od 393 rezistentne varijante otkrivene u 255 bolesnika, više se nije moglo otkriti 68% NS3-36, 84% NS3-54, 59% NS3-155, 86% NS3-156 i 52% NS3-36M+NS3-155K varijanti.
In vitro studies demonstrated that telaprevir is not an inhibitor of UGT1A9 or UGT2B7. 
In vitro ispitivanja su pokazala da telaprevir ne inhibira UGT1A9 ili UGT2B7.
Interruption of ribavirin may be required sooner if the rash worsens despite discontinuation of telaprevir. 
Primjenu ribavirina treba prekinuti i prije ako se osip nastavi pogoršavati unatoč prekidu primjene telaprevira.
Severe, potentially life-threatening and fatal skin reactions have been reported with INCIVO combination treatment. 
Teške, potencijalno po život opasne i fatalne kožne reakcije prijavljene su uz kombinirano liječenje s lijekom INCIVO.
Syncope and retinopathy have been reported in some patients taking INCIVO and should be considered when assessing a patient's ability to drive or operate machines. 
U nekih bolesnika koji uzimaju INCIVO zabilježene su sinkopa i retinopatija, koje treba uzeti u obzir kad se procjenjuje bolesnikova sposobnost upravljanja vozilima i rada sa strojevima.
The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia (see section 4.4). 
Ova kombinacija može rezultirati povećanim rizikom kardiovaskularnih nuspojava povezanih sa salmeterolom, uključujući produljenje QT intervala, palpitacije i sinusnu tahikardiju (vidjeti dio 4.4).
You should contact your doctor immediately if you develop a rash or have a rash that gets worse. 
Odmah se trebate javiti liječniku ako dobijete osip ili vam se osip pogorša.
astemizole, terfenadine to treat allergy symptoms (antihistamines) 
astemizol, terfenadin za liječenje simptoma alergija (antihistaminici)
The clinical relevance of this is uncertain as administration of telaprevir with a single dose of buprenorphine, a partial UGT1A3 substrate, to healthy adult subjects did not result in increases in buprenorphine exposures. 
Klinički značaj ovog nalaza nije siguran, obzirom da primjena telaprevira s jednom dozom buprenorfina, djelomičnog supstrata UGT1A3, zdravim odraslim ispitanicima nije dovela do povećene izloženosti buprenorfinu.
only includes data on patients who had week 4 HCV RNA available 
Uključuje samo bolesnike za koje su bili dostupni podaci o HCV RNK u 4. tjednu
Fertility INCIVO had no effects on fertility or fecundity when evaluated in rats. 
Plodnost INCIVO nije imao učinaka na plodnost ni oplodnju kada se ispitivao u štakora.
During this time, female patients of childbearing potential should use two effective non-hormonal methods of contraception. 
Za to vrijeme, bolesnice reproduktivne dobi trebaju koristiti dvije učinkovite nehormonske metode kontracepcije.
When INCIVO is used in patients with advanced liver disease very close monitoring and early management of adverse events is recommended. 
Kada INCIVO uzimaju bolesnici s uznapredovalom bolešću jetre, preporučen je strogi nadzor i rano zbrinjavanje
In patients who have an inadequate viral response, treatment should be discontinued (see sections 4.2 and 4.4, Laboratory tests). 
Liječenje treba prekinuti u bolesnika koji imaju neodgovarajući virusni odgovor (vidjeti dijelove 4.2 i 4.4, Laboratorijske pretrage).
Telaprevir has not been tested for its carcinogenic potential. 
Kancerogeni potencijal telaprevira nije ispitivan.
All patients N = 74 % (n/N) 
Svi bolesnici N = 74 % (n/N)
Telaprevir-resistant variants were tested for cross-resistance against representative protease inhibitors in the HCV replicon system. 
Za varijante rezistentne na telaprevir bila je ispitana ukrižena rezistencija na reprezentativne inhibitore proteaze u HCV replikonskom sustavu.
In patients with normal renal and hepatic function, an interruption of colchicine treatment is recommended, or only a limited colchicine treatment course at a reduced colchicine dose should be used. 
U bolesnika s normalnom funkcijom bubrega ili jetre, preporučuje se prekid liječenja kolhicinom ili primjena samo kratke kure liječenja smanjenom dozom kolhicina.
In an HCV subtype 1b replicon assay, the telaprevir IC50 value against wild-type HCV was 0.354 µM similar to a subtype 1a infectious virus assay IC50 of 0.28 µM. 
U testu replikona HCV-a podtipa 1b, IC50 vrijednost telaprevira protiv divljeg tipa HCV-a od 0,354 µM, bila je slična IC50 vrijednosti od 0,28 µM u testu s infektivnim virusom podtipa 1a.
The total duration of treatment of peginterferon alfa and ribavirin varies from 24 to 48 weeks depending on treatment response and whether you have been treated before. 
Ukupno trajanje liječenja peginterferonom alfa i ribavirinom varira od 24 do 48 tjedana, ovisno o terapijskom odgovoru i o tome jeste li se već prije liječili.
Increase in thyroid stimulating hormone (TSH) may occur during INCIVO combination treatment, which may indicate worsening or recurrence of pre-existing or previous hypothyroidism, or new-onset hypothyroidism (see section 4.8). 
Tijekom kombiniranog liječenja INCIVOM može se povisiti koncentracija tiroidnog stimulirajućeg hormona (TSH), što može ukazivati na pogoršanje postojeće ili povratak prethodne hipotireoze ili novonastalu hipotireozu (vidjeti dio 4.8).
Histopathological findings in the liver were similar in both rat and dog studies, of which not all were fully resolved after recovery. 
Patohistološki nalazi jetre u ispitivanjima na štakorima i onima na psima bili su slični, s tim da se nisu svi povukli nakon oporavka.
In the analysis of an additional study, Study C211, the safety profile of combination therapy with INCIVO 1,125 mg twice daily was similar to the safety profile for patients receiving combination therapy with INCIVO 750 mg every 8 hours. 
U analizi dodatnog ispitivanja, Ispitivanja C211, sigurnosni profil kombiniranog liječenja s lijekom INCIVO 1125 mg dva puta na dan bio je sličan sigurnosnom profilu za bolesnike koji primaju kombinirano liječenje s lijekom INCIVO 750 mg svakih 8 sati.
Concomitant use may lead to adverse events such as nausea, dizziness, hypotension and syncope. 
Istodobna primjena može dovesti do nuspojava kao što su mučnina, omaglica, hipotenzija i sinkopa.
If improvement is not observed within 7 days of INCIVO discontinuation, sequential or simultaneous interruption or discontinuation of ribavirin and/or peginterferon alfa should be considered. 
Ako se ne primijeti poboljšanje unutar 7 dana nakon prekida primjene INCIVA, potrebno je razmotriti prekid i prestanak primjene ribavirina i/ili peginterferona alfa, istodobno ili jednog za drugim.
Administration of INCIVO may increase systemic exposure to medicinal products that are substrates of CYP3A or P-gp, which could increase or prolong their therapeutic effect and adverse reactions. 
Primjena INCIVA može povisiti sistemsku izloženost lijekovima koji su supstrati CYP3A ili P-gp, što može povisiti ili produžiti njihov terapijski učinak i nuspojave.
Tell your doctor if you have heart failure, irregular heartbeat, slow heart rate, an abnormality shown in your heart tracing (ECG) called 'long QT syndrome', or a family history of a heart condition called 'congenital QT syndrome'. 
Obavijestite svog liječnika ako imate zatajenje srca, nepravilne otkucaje srca, usporene otkucaje srca, poremećaj koji se vidi na elektrokardiogramu (EKG) a naziva se “sindrom produljenog QT intervala” ili ako Vam je netko u obitelji imao srčani poremećaj koji se naziva “kongenitalni sindrom produljenog QT intervala”.
Due to the combined treatment with peginterferon alfa and ribavirin, female patients of childbearing potential and their male partners as well as male patients and their female partners must use 2 effective contraceptive methods during INCIVO treatment. 
Zbog kombiniranog liječenja s peginterferonom alfa i ribavirinom, bolesnice reproduktivne dobi i njihovi partneri, kao i muški bolesnici i njihove partnerice, moraju koristiti 2 učinkovite kontracepcijske metode za vrijeme liječenja INCIVOM.
If you need help, ask your doctor or pharmacist. 
Ako Vam je potrebna pomoć, upitajte svog liječnika ili ljekarnika.
Efavirenz: with this combination the telaprevir dose must be increased to 1,125 mg three times per day (q8h). 
Efavirenz: u ovoj kombinaciji doza telaprevira mora se povisiti na 1125 mg, tri puta na dan (svakih 8 sati).
All telaprevir-resistant variants studied remained fully sensitive to interferon-alfa, ribavirin, and representative HCV nucleoside and non-nucleoside polymerase inhibitors in the replicon system. 
Sve ispitane varijante rezistentne na telaprevir ostale su potpuno osjetljive na interferon-alfa, ribavirin i nukleozidne i nenukleozidne reprezentativne inhibitore HCV polimeraze u replikonskom sustavu.
The lower limit of the 95% CI (-4.9%) was greater than the pre-determined noninferiority margin of -11% and therefore the non inferiority of T12(b.i.d. 
Niža granica 95% CI (-4,9%) bila je veća od unaprijed određene margine neinferiornosti od -11% te je stoga pokazana neinferiornost T12(b.i.d.)/PR u usporedbi s T12(q8h)/PR.
Similar proportions of patients in both treatment groups had telaprevir-resistant variants at the time of failure. 
Slični udjeli bolesnika u obje liječene skupine imale su, u vrijeme neuspjeha, varijante rezistentne na telaprevir.
Fifty-five out of 60 patients received ribavirin at a fixed dose of 800 mg/day and the remaining 5 patients received a weight-based ribavirin dose. 
Pedeset i pet od 60 bolesnika primalo je ribavirin stalne doze od 800 mg/na dan, a preostalih 5 bolesnika primalo je dozu ribavirina ovisno o tjelesnoj težini.
ECG should be monitored at baseline and regularly during telaprevir treatment. 
Potrebno je snimiti EKG na početku i redovito tijekom liječenja telaprevirom.
Since INCIVO must be used in combination with ribavirin and ribavirin can be very damaging to an unborn baby, both female and male patients must take special precautions in order to prevent pregnancy. 
Obzirom da se INCIVO mora uzimati u kombinaciji s ribavirinom koji može biti vrlo štetan za nerođeno dijete, i žene i muškarci moraju poduzeti posebne mjere opreza za sprječavanje trudnoće.
The assay had a lower limit of quantification of 25 IU/ml. 
Test je imao donju granicu kvantifikacije od samo 25 IU/ml.
There is limited pharmacokinetic data on the use of INCIVO in HCV patients aged ≥ 65 years and no data in subjects > 70 years of age. 
Postoje samo ograničeni farmakokinetički podaci o primjeni INCIVA u bolesnika s HCV-infekcijom s ≥ 65 godina starosti, dok podaci za osobe s > 70 godina starosti ne postoje.
Maraviroc 150 mg twice daily when co-administered with telaprevir. 
Kada se Maravirok 150 mg, dva puta na dan, primjenjuje istodobno s telaprevirom.
The median time for telaprevir-resistant variants to become undetectable by population sequencing was longer for variants NS3-36 (6 months), NS3-155 (9 months) and NS3-36M+NS3-155K (12 months) predominantly observed in patients with genotype 1a than for variants NS3-54 (2 months) and NS3-156 (3 months) predominantly observed in patients with genotype 1b. 
Medijan vremena do nemjerljivosti varijanti rezistentnih na telaprevir prema populacijskoj analizi nukleotidnih sljedova genoma, bilo je dulje za varijante NS3-36 (6 mjeseci), NS3-155 (9 mjeseci) i NS3-36M+NS3-155K (12 mjeseci) pretežno opažene u bolesnika s genotipom 1a nego za varijante NS3-54 (2 mjeseca) i NS3-156 (3 mjeseca) pretežno opažene u bolesnika s genotipom 1b.
(< 25,000/mm absolute lymphocyte count 
(< 25 000/mm apsolutni broj limfocita
Signs and symptoms of dehydration include increased thirst, dry mouth, decreased urine frequency or volume, and dark coloured urine. 
Znakovi i simptomi dehidracije uključuju pojačanu žeđ, suha usta, smanjenu učestalost ili količinu mokrenja i mokraću tamne boje.
The highest documented INCIVO dose administered is 1,875 mg every 8 hours for 4 days in healthy volunteers. 
Najviša primijenjena zabilježena doza INCIVA iznosi 1875 mg svakih 8 sati tijekom 4 dana u zdravih ispitanika.
No studies on the effects of INCIVO on the ability to drive and use machines have been performed. 
Nisu provedena ispitivanja učinaka INCIVA na sposobnost upravljanja vozilima i rada sa strojevima.
Co-administration of sildenafil or tadalafil and telaprevir in the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3). 
Istodobna primjena sildenafila ili tadalafila i telaprevira u liječenju plućne arterijske hipertenzije je kontraindicirana (vidjeti dio 4.3).
Table 14: Pooled response rates: Study C208 
Tablica 14: Objedinjene stope odgovora: Ispitivanje C208
If a patient achieved undetectable HCV RNA (target not detected) at week 4, the total treatment duration was 24 weeks. 
Ako je bolesnik postigao nemjerljivu HCV RNK (cilj nije izmjeren) u 4. tjednu, ukupno trajanje liječenja bilo je 24 tjedna.
In general, exposure levels in relation to human values were low in animal pharmacology and toxicology studies. 
Općenito, razine izloženosti u farmakološkim i toksikološkim ispitivanjima na životinjama bile su niže u odnosu na vrijednosti u ljudi.
Patients receiving cyclosporine A N = 24 % (n/N) 
Bolesnici koji su primali ciklosporin A N = 24 % (n/N)
The denominator when calculating the relapse rate represents the number of patients with end-of-treatment response (HCV RNA < 25 IU/ml). 
Nazivnik pri izračunu stope relapsa predstavlja broj bolesnika s odgovorom na kraju liječenja (HCV RNK < 25 IU/ml).
Increased clinical and laboratory monitoring are warranted (see section 4.4). 
Nalaže se pojačan klinički i laboratorijski nadzor (vidjeti dio 4.4).
Refer to section 4.5 for established and other potentially significant drug-drug interactions. 
Vidjeti dio 4.5 za ustanovljene i druge potencijalno značajne
Taking INCIVO without food or without regard to the dosing interval may result in decreased plasma concentrations of telaprevir which could reduce the 
Uzimanje INCIVA bez hrane ili nepridržavanje preporučenog doziranja može dovesti do smanjene koncentracije telaprevira u plazmi te smanjenja terapijskog učinka INCIVA.
Such patients should be closely monitored, including ECG assessments. 
Takve bolesnike treba pomno pratiti, uključujući EKG praćenje.
Sildenafil or tadalafil must not be used to treat a heart and lung disorder called pulmonary arterial hypertension. 
Sildenafil ili tadalafil se ne smiju primjenjivati za liječenje poremećaja srca i pluća koji se zove plućna arterijska hipertenzija.
Patients were randomised in a 2:2:1 ratio to one of three treatment groups: simultaneous start (T12/PR48): INCIVO from day 1 through week 12; delayed start (T12(DS)/PR48): INCIVO from week 5 through week 16; Pbo/PR48: placebo through week 16. 
Bolesnici su bili randomizirani u omjeru 2:2:1 u jednu od tri terapijske skupine: istodobni početak (T12/PR48): INCIVO od 1. dana do 12. tjedna; odgođeni početak (T12(DS)/PR48): INCIVO od 5. tjedna do 16. tjedna; Pbo/PR48: placebo do 16. tjedna.
To manage anaemia, at initiation of INCIVO treatment a lower starting dose of ribavirin (600 mg/day) was used; during the overall treatment phase the ribavirin dose was further reduced in 36.5% of patients, 41.9% received ESAs and 21.6% received blood transfusions (see sections 4.4 and 4.5, Immunosuppressants). 
Zbog zbrinjavanja anemije, na početku liječenja INCIVOM koristila se niža početna doza ribavirina (600 mg/dan); tijekom ukupne faze liječenja doza ribavirina je dalje snižena u 36,5% bolesnika, 41,9% je primilo lijekove koji stimuliraju eritropoezu, a 21,6% je primilo transfuzije krvi (vidjeti djelove 4.4 i 4.5, Imunosupresivi).
After the end of INCIVO treatment, uric acid values typically decrease over the following 8 weeks and are comparable to those observed in patients receiving peginterferon alfa and ribavirin alone. 
Nakon završetka liječenja INCIVOM, vrijednosti mokraćne kiseline obično se smanjuju tijekom sljedećih 8 tjedana i postaju usporedive s vrijednostima opaženima u bolesnika koji primaju samo peginterferon alfa i ribavirin.
Clinical and laboratory monitoring for hyperbilirubinaemia is recommended (see section 4.4 and 4.8). 
Preporučuje se kliničko i laboratorijsko praćenje zbog hiperbilirubinemije (vidjeti dio 4.4 i 4.8).